Global Pulmonary Arterial Hypertension Market Report 2023: Growing Prevalence of Lung Cancer and Other Lung Related Disorders Drives Sector
May 31, 2023 07:23 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and...
Global Pulmonary Arterial Hypertension Market Report 2021: Market Leaders Opsumit and Uptravi are Being Investigated in Clinical Trials to Potentially Support Label Expansions to CTEPH
June 09, 2021 08:58 ET
|
Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The report...
Global Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast to 2030
November 24, 2020 16:38 ET
|
Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 06, 2016 08:00 ET
|
SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
January 05, 2016 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
December 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results
November 05, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting
October 28, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
October 21, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Participate in Upcoming Investor Conferences
September 02, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...